NCI to Study Ivermectin for Cancer: Controversy & Scientific Concerns

The National Cancer Institute (NCI) is undertaking a new study to investigate the potential of Ivermectin, a drug primarily used to treat parasitic infections, to kill cancer cells. This decision, made by NCI Director Anthony Letai, who was appointed by the administration of US President Donald Trump last September, follows reports and public interest in the drug’s possible anti-cancer properties.

A Controversial Path

The NCI, historically a global leader in cancer therapy discovery, will conduct improved preclinical studies – involving cell cultures and animal testing – to assess Ivermectin’s capabilities. Letai stated that results from these studies are expected within a few months, prompting the institute to take the matter “seriously.” However, the decision has sparked concern among some scientists within the NCI.

One NCI scientist, speaking anonymously, expressed “shock and dismay,” stating that funding is being diverted from promising research projects to support a study based on “unscientific assumptions.” This scientist characterized the undertaking as “absurd.”

Did You Know? William C. Campbell and Satoshi Omura received the 2015 Nobel Prize in Medicine for the discovery of Ivermectin.

From COVID-19 to Cancer Research

Ivermectin gained prominence during the COVID-19 pandemic, promoted by alternative medicine groups as a treatment for the virus. However, clinical trials consistently demonstrated its ineffectiveness against COVID-19. The announcement of the new cancer research occurred at an event hosted by the “Make America Healthy Again” (MAHA) Institute in Washington, D.C., an organization aligned with the policies of US Health Minister Robert F. Kennedy Jr.

Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) cautioned against using Ivermectin to treat COVID-19, warning of potentially life-threatening complications at higher dosages. Despite these warnings, Ivermectin remained a symbol of resistance against established medicine for supporters of the MAHA initiative and conservatives in the US.

Expert Insight: The NCI’s decision to pursue this research, despite existing scientific skepticism and the drug’s controversial history, highlights the complex interplay between public interest, political influences, and scientific inquiry in shaping research priorities.

Proponents of the research, including Jay Bhattacharya, head of the National Institutes of Health (NIH), argue that public belief and potential impact on public health necessitate further investigation. It’s important to note that Ivermectin is a “blessing” for millions, particularly in tropical regions, and is also used in veterinary medicine.

Frequently Asked Questions

What prompted the NCI to study Ivermectin for cancer treatment?

Reports and public interest in Ivermectin’s potential to kill cancer cells led the NCI to initiate preclinical studies, according to Anthony Letai.

What concerns have been raised about this research?

Some scientists within the NCI have expressed concern that funding is being diverted from other promising research projects to support a study based on what they consider “unscientific assumptions.”

Was Ivermectin proven effective against COVID-19?

No, clinical trials demonstrated the ineffectiveness of Ivermectin as a treatment for COVID-19.

As research progresses, it remains to be seen whether Ivermectin will demonstrate any meaningful anti-cancer effects, and further studies will be crucial to determine its potential role in cancer treatment.